U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085572) titled 'Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer' on July 16.
Brief Summary: This clinical trial is a single-arm, non-randomized, prospective phase II study.
The study aims to evaluate if the maintenance immunotherapy with cemiplimab in patients with AdrenoCortical Carcinoma (ACC), who obtained disease response or stabilization after first-line chemotherapy, may delay/prevent disease progression.
The study will be conducted at ASST Spedali Civili Hospital, Brescia - Italy.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Adrenal Cortical Carcinoma
Intervention:
DRUG: Cemiplimab
350 mg...